Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic Agents In Vitro
Table 1
Characteristic of CLL patients.
Sex
Age
Stage of CLL
Leukocytosis [×109/L]
Chromosomal abnormalities [analyzed by FISH technique]
Sensitivity of PBMC to CM [% of dead cells in comparison to control]
Sensitivity of PBMC to 10 μM, 25 μM, and 50 μM atorvastatin, respectively [% of dead cells in comparison to control]
1
M
80
II
75
del 13q14
38% S
14.1%
17.5%
29.9%
2
M
51
I
46
del 11q22
54% S
12.7%
26.7%
51.9%
3
M
68
I
300
del 13q14
78.2% S
19.2%
29.7%
47.1%
4
M
77
IV
300
del 11q22, del 13q14
3.7% R
4.7%
15.2%
30.3%
5
M
53
I
64
N
67.4% S
15.4%
27.2%
46.8%
6
F
60
IV
300
ND
64.8% S
20.3%
35.1%
32.8%
7
M
56
III
224
ND
60.4% S
22.1%
25.3%
35.4%
8
M
75
III
200
N
41.8% S
20.2%
27.8%
40.3%
9
M
69
IV
300
del 13q14
10.4% R
16.6%
25.4%
41.6%
10
M
65
II
260
del 13q14
77.4% S
20.7%
28%
42%
11
F
72
III
129
del 17p13
14.7% R
9.8%
16.8%
27.8%
12
M
56
IV
136
del 13q14
64.5% S
19.5%
29.3%
49.2%
13
M
72
II
220
ND
50% S
29.7%
48.8%
71.55%
14
M
68
III
170
del 13q14
45.1% S
31%
43.9%
55.2%
15
M
59
IV
190
del 13q14
10.8% R
12%
27.1%
45.2%
16
F
65
II
180
N
30.2% S
20.7%
25%
28.5%
17
F
63
IV
150
del 13q14
2.7% R
26.2%
38.8%
46.6%
18
F
56
IV
350
N
4.4% R
34.7%
51.9%
75.3%
19
M
66
IV
600
del 13q14, del 11q22, +12
18.7% P
12.1%
27.1%
49.4%
20
M
61
I
150
+12
2.4% R
1.6%
8.8%
13%
21
F
81
I
28
ND
26.3% P
7.9%
22.9%
29.9%
22
M
80
III
30
ND
42.3% S
5.7%
7.5%
21.1%
23
M
59
0
80
del 11q22
16% P
10.5%
1.6%
10.8%
24
M
71
I
77
ND
18.6% P
11.1%
14.4%
21.8%
*Atypical CLL with only 15% of CD5+/CD19+ cells, N: normal karyotype, ND: not determined, +12: trisomy 12, del: deletion, F: female, M: male, P: PBMCs partially sensitive to cladribine + mafosfamide drug combination, S: PBMCs sensitive to cladribine + mafosfamide, and R: PBMCs resistant to cladribine + mafosfamide.
